1
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R: Gynecologic Oncology Group. Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200.
2003.PubMed/NCBI View Article : Google Scholar
|
2
|
du Bois A, Lück HJ, Meier W, Adams HP,
Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, et
al: A randomized clinical trial of cisplatin/paclitaxel versus
carboplatin/paclitaxel as first-line treatment of ovarian cancer. J
Natl Cancer Inst. 95:1320–1329. 2003.PubMed/NCBI View Article : Google Scholar
|
3
|
Takei Y, Suzuki M, Ohwada M, Saga Y, Kohno
T, Machida S and Sato I: A feasibility study of paclitaxel and
carboplatin therapy in Japanese patients with epithelial ovarian
cancer. Oncol Rep. 10:951–955. 2003.PubMed/NCBI
|
4
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al: Incorporation of bevacizumab in the primary treatment of
ovarian cancer. N Engl J Med. 365:2473–2483. 2011.PubMed/NCBI View Article : Google Scholar
|
5
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al: A phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med. 365:2484–2496. 2011.PubMed/NCBI View Article : Google Scholar
|
6
|
Katsumata N, Yasuda M, Takahashi F,
Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura
E, et al: Dose-dense paclitaxel once a week in combination with
carboplatin every 3 weeks for advanced ovarian cancer: A phase 3,
open-label, randomised controlled trial. Lancet. 374:1331–1338.
2009.PubMed/NCBI View Article : Google Scholar
|
7
|
Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke
GS, et al: Maintenance olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med. 379:2495–2505.
2018.PubMed/NCBI View Article : Google Scholar
|
8
|
González-Martín A, Pothuri B, Vergote I,
DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D,
Hoskins P, Freyer G, et al: Niraparib in patients with newly
diagnosed advanced ovarian cancer. N Engl J Med. 381:2391–2402.
2019.PubMed/NCBI View Article : Google Scholar
|
9
|
Ray-Coquard I, Pautier P, Pignata S, Pérol
D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N,
Mäenpää J, et al: Olaparib plus Bevacizumab as First-Line
Maintenance in Ovarian Cancer. N Engl J Med. 381:2416–2428.
2019.PubMed/NCBI View Article : Google Scholar
|
10
|
Cancer Therapy Evaluation Program: Common
Toxicity Criteria. Version 2.0, 1999. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf.
Accessed October 23, 2021.
|
11
|
Prat J: FIGO Committee on Gynecologic
Oncology. Staging classification for cancer of the ovary, fallopian
tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5.
2014.PubMed/NCBI View Article : Google Scholar
|
12
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events. Version 4.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
Accessed August 15, 2021.
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
14
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
15
|
Pignata S, Scambia G, Katsaros D, Gallo C,
Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F,
Panici PB, et al: Carboplatin plus paclitaxel once a week versus
every 3 weeks in patients with advanced ovarian cancer (MITO-7): A
randomised, multicentre, open-label, phase 3 trial. Lancet Oncol.
15:396–405. 2014.PubMed/NCBI View Article : Google Scholar
|
16
|
Ma BB, Hui EP and Mok TS: Population-based
differences in treatment outcome following anticancer drug
therapies. Lancet Oncol. 11:75–84. 2010.PubMed/NCBI View Article : Google Scholar
|
17
|
Watanabe Y, Nakai H, Ueda H and Hoshiai H:
Evaluation of weekly low-dose paclitaxel and carboplatin treatment
for patients with platinum-sensitive relapsed ovarian cancer.
Gynecol Oncol. 96:323–329. 2005.PubMed/NCBI View Article : Google Scholar
|
18
|
Takaya H, Nakai H, Murakami K, Tobiume T,
Suzuki A, Mandai M and Matsumura N: Efficacy of weekly
administration of paclitaxel and carboplatin for advanced ovarian
cancer patients with poor performance status. Int J Clin Oncol.
23:698–706. 2018.PubMed/NCBI View Article : Google Scholar
|
19
|
Clamp AR, James EC, McNeish IA, Dean A,
Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, et
al: Weekly dose-dense chemotherapy in first-line epithelial
ovarian, fallopian tube, or primary peritoneal carcinoma treatment
(ICON8): Primary progression free survival analysis results from a
GCIG phase 3 randomised controlled trial. Lancet. 394:2084–2095.
2019.PubMed/NCBI View Article : Google Scholar
|
20
|
Han JJ, Kim YJ, Kim JW, Chang H, Lee JO,
Lee KW, Jeong CW, Kim JH, Hong SK, Bang SM, et al: Salvage
treatment with low-dose weekly paclitaxel in elderly or poor
performance status patients with metastatic urothelial carcinoma.
Tumori. 100:439–445. 2014.PubMed/NCBI View Article : Google Scholar
|